PMID- 17018856
OWN - NLM
STAT- MEDLINE
DCOM- 20070306
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 109
IP  - 3
DP  - 2007 Feb 1
TI  - Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for 
      standard and high-risk Hodgkin lymphoma with no impairment of outcome.
PG  - 905-9
AB  - Therapy of Hodgkin disease (HD) is designed to prolong progression-free survival 
      and minimize toxicity. The best regimen to achieve this has not yet been defined. 
      A total of 108 patients with newly diagnosed HD and adverse prognostic factors 
      were prospectively studied between 1999 and 2004. They were assigned to therapy 
      according to defined risk stratification. Patients were defined depending on the 
      International Prognostic Score (IPS). Those with IPS of 3 or higher received 2 
      cycles of escalated therapy, including bleomycin, etoposide, doxorubicin, 
      cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP [EB]). All 
      others received 2 cycles of standard BEACOPP (SB). Subsequent therapy was 
      prospectively assigned following 2 cycles according to results of early interim 
      67Ga or positron emission tomography/computed tomography (PET/CT). Following a 
      positive interim scan, 4 cycles of EB were administered, whereas 4 cycles of SB 
      were given to patients with a negative scan. The complete remission rate, the 
      5-year event-free survival (EFS), and overall survival (OS) rates were 97%, 85% 
      and 90%, respectively. Relapse or progression occurred in 27% of patients with 
      interim positive PET/CT versus 2.3% of negative scans (P<.02). Early interim 
      fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT is a useful tool for 
      adjustment of chemotherapy on an individual basis. Similar EFS and OS rates were 
      observed for patients in both risk groups.
FAU - Dann, Eldad J
AU  - Dann EJ
AD  - Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, 
      Haifa, Israel. e_dann@rambam.health.gov.il
FAU - Bar-Shalom, Rachel
AU  - Bar-Shalom R
FAU - Tamir, Ada
AU  - Tamir A
FAU - Haim, Nissim
AU  - Haim N
FAU - Ben-Shachar, Menachem
AU  - Ben-Shachar M
FAU - Avivi, Irit
AU  - Avivi I
FAU - Zuckerman, Tzila
AU  - Zuckerman T
FAU - Kirschbaum, Mark
AU  - Kirschbaum M
FAU - Goor, Odelia
AU  - Goor O
FAU - Libster, Diana
AU  - Libster D
FAU - Rowe, Jacob M
AU  - Rowe JM
FAU - Epelbaum, Ron
AU  - Epelbaum R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20061003
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 11056-06-7 (Bleomycin)
RN  - 35S93Y190K (Procarbazine)
RN  - 5J49Q6B70F (Vincristine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - BEACOPP protocol
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use/toxicity
MH  - Bleomycin/administration & dosage
MH  - Cyclophosphamide/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Drug Monitoring/methods
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Hodgkin Disease/*diagnosis/*drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Positron-Emission Tomography
MH  - Prednisone/administration & dosage
MH  - Procarbazine/administration & dosage
MH  - Prognosis
MH  - Prospective Studies
MH  - Remission Induction
MH  - Risk
MH  - Survival Analysis
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage
EDAT- 2006/10/05 09:00
MHDA- 2007/03/07 09:00
CRDT- 2006/10/05 09:00
PHST- 2006/10/05 09:00 [pubmed]
PHST- 2007/03/07 09:00 [medline]
PHST- 2006/10/05 09:00 [entrez]
AID - S0006-4971(20)51971-X [pii]
AID - 10.1182/blood-2006-04-019901 [doi]
PST - ppublish
SO  - Blood. 2007 Feb 1;109(3):905-9. doi: 10.1182/blood-2006-04-019901. Epub 2006 Oct 
      3.